BUMINATE 25% 25 % — DIN 00118303
ALBUMIN (HUMAN) : 25 % · BAXTER HEALTHCARE CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is BUMINATE 25%?
BUMINATE 25% 25 % contains ALBUMIN (HUMAN) : 25 %. It is listed in the Health Canada Drug Product Database under DIN 00118303, held by BAXTER HEALTHCARE CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 06-Feb-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is BUMINATE 25% used for?
BUMINATE 5% and BUMINATE 25% are indicated for the treatment of hypovolemia and hypoalbuminemia, including that experienced during extensive burns and adult respiratory distress syndrome (BUMINATE 25% only), nephrosis (BUMINATE 25% only) and cardiopulmonary bypass surgery. It is not indicated as an intravenous nutrient.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Albumin cost around the world?
Albumin is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 6 | 17 | CZK███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 16 | NOK███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Iceland | max wholesale | 5 | 10 | ISK███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
| Hungary | producer price (ex-factory) | 1 | 2 | HUF███.██ |
60 pack listings across 31 brand entries and 5 price bases, refreshed 07 Sep 2026. Ranges span every Albumin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Albumin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Albumin, across 20 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GRIFOLS THERAPEUTICS LLC | 4 | 3 | ALBUMIN (HUMAN) 25% SOLUTION USP, ALBUMIN (HUMAN) 5% SOLUTION, USP, PLASBUMIN-25, PLASBUMIN-5 | Sourceable in Canada |
| CSL BEHRING CANADA INC | 2 | 2 | ALBUREX - 25, ALBUREX - 5 | Sourceable in Canada |
| CUTTER MED & BIOL, DIVISION OF MILES CANADA LTD. | 3 | 0 | NORMAL SERUM ALBUMIN HUMAN 25% USP, PLASBUMIN-5 INJ 50MG/ML, PLASMANATE INJ 0.05GM/ML USP | No marketed DIN |
| BAXTER AG | 2 | 0 | ALBUMIN (HUMAN) 25% SOLUTION, ALBUMIN (HUMAN) 5% SOLUTION | No marketed DIN |
| BAXTER HEALTHCARE CORPORATION | 2 | 0 | BUMINATE 25%, BUMINATE 5% | No marketed DIN |
| GRIFOLS BIOLOGICALS LLC | 2 | 0 | ALBUTEIN 25% SOLN USP, ALBUTEIN 5% SOLN USP | No marketed DIN |
| OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | 2 | 0 | OCTALBIN 25%, OCTALBIN 5% | No marketed DIN |
| BEHRINGWERKE AG | 1 | 0 | HUMANALBIN INJ 5% | No marketed DIN |
| INSTITUTO GRIFOLS S.A. | 1 | 0 | HUMAN ALBUMIN GRIFOLS 20% | No marketed DIN |
| ZLB BEHRING LLC | 1 | 0 | ALBUMINAR-25 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 25 % |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | BUMINATE 5%, Albumin (Human), 5% Solution is supplied in 250 mL and 500 mL bottles containing 12.5 g or 25.0 g of albumin respectively. BUMINATE 25%, Albumin (Human), 25% Solution is supplied in 20 mL, 50 mL, and 100 mL bottles containing 5.0 g, 12.5 g or 25.0 g of albumin, respectively. |
| Storage | Store at room temperature, not to exceed 30°C (86°F). Avoid freezing to prevent damage to the bottle. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Albumin |
|---|---|
| ATC code | B05AA01 |
| AHFS class | 16:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00118303 |
|---|---|
| DIN (unpadded, as printed on some documents) | 118303 |
| Brand name | BUMINATE 25% |
| Generic / active ingredient | ALBUMIN (HUMAN) : 25 % |
| Market authorization holder | BAXTER HEALTHCARE CORPORATION |
| Health Canada schedule | Schedule D |
| ATC code | B05AA01 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05AA |
| Current status | CANCELLED POST MARKET |
| Status date | 06-Feb-2015 |
| Original market date | 1955-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALBUMIN (HUMAN) 25% SOLUTION USP | 25 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02223708 |
| ALBUMIN (HUMAN) 5% SOLUTION, USP | 5 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02223694 |
| ALBUREX - 25 | 25 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02274663 |
| ALBUREX - 5 | 5 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02274655 |
| PLASBUMIN-5 | 50 MG | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02189100 |
| ALBUMIN (HUMAN) 25% SOLUTION | 25 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | 00427659 |
| ALBUMIN (HUMAN) 5% SOLUTION | 5 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | 00427675 |
| ALBUMINAR-25 | 25 G / 100 ML | SOLUTION | ZLB BEHRING LLC | CANCELLED POST MARKET | 00624608 |
| ALBUTEIN 25% SOLN USP | 250 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | 00779571 |
| ALBUTEIN 5% SOLN USP | 50 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | 00779563 |
2 · Same class — other molecules in ATC B05AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Albumin | ALBUMIN (HUMAN) 25% SOLUTION · ALBUMIN (HUMAN) 25% SOLUTION USP · ALBUMIN (HUMAN) 5% SOLUTION · ALBUMIN (HUMAN) 5% SOLUTION, USP · +16 more | 20 | 5 | Yes |
| Dextran,Combinations | 10% DEXTRAN 40 IN 0.9% SODIUM CHLORIDE INJECTION · 10% DEXTRAN 40 IN 5% DEXTROSE INJECTION · 6% DEXTRAN 70 IN 0.9% SODIUM CHLORIDE INJECTION · DEXTRAN 6% IN 0.9% SODIUM CHLORIDE INJECTION · +10 more | 14 | 2 | Yes |
| Hydroxyethylstarch | HEXTEND · PENTASPAN · VOLULYTE · VOLUVEN | 4 | 2 | Yes |
| Other Plasma Protein Fractions | PLAS+SD · PLASMA PROTEIN FRACTION (HUMAN) PROTENATE | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05AX | Blood Plasma | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BUMINATE 25% called?
The same molecule, Albumin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Alburex | Latin | Czechia, Iceland, Norway |
| ALBUTEIN | Latin | Czechia, Iceland |
| Albunorm | Latin | Czechia, Norway |
| Albumin Grifols | Latin | Norway |
| Flexbumin | Latin | Czechia, Iceland, Norway |
| Albumin Baxalta | Latin | Iceland, Norway |
| HUMAN ALBUMIN BAXALTA | Latin | Czechia |
| HUMAN ALBUMIN CSL BEHRING | Latin | Czechia |
| HUMAN ALBUMIN OCTAPHARMA | Latin | Bahrain |
| Albuman | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.